Literature DB >> 15234104

The up-regulation of the striatal dopamine transporter's activity by cAMP is PKA-, CaMK II- and phosphatase-dependent.

Guylène Page1, Stéphanie Barc-Pain, Raymond Pontcharraud, Arnaud Cante, Alain Piriou, Laurence Barrier.   

Abstract

The neuronal dopamine transporter (DAT) is a presynaptic plasma membrane protein mediating the re-uptake of dopamine released from synaptic cleft into the nerve terminals. While the regulation of its activity by protein kinase C signalling is well-characterized, there is controversial debate about its regulation by protein kinase A (PKA) signalling. In rat striatal synaptosomes, we showed that a cell-permeable cyclic adenosine 3',5'-monophosphate analogue up-regulated the DAT capacity without modification of its efficiency. This acute effect was PKA-, calcium calmodulin dependent kinase II- and phosphatase-dependent. Together, these results suggest that the activity of DAT may depend on a state of the transporter with both specific phosphorylated and dephosphorylated sites.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15234104     DOI: 10.1016/j.neuint.2004.04.002

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  12 in total

1.  Dephosphorylation of human dopamine transporter at threonine 48 by protein phosphatase PP1/2A up-regulates transport velocity.

Authors:  Jae-Won Yang; Garret Larson; Lisa Konrad; Madhur Shetty; Marion Holy; Kathrin Jäntsch; Mirja Kastein; Seok Heo; Fatma Asli Erdem; Gert Lubec; Roxanne A Vaughan; Harald H Sitte; James D Foster
Journal:  J Biol Chem       Date:  2018-12-26       Impact factor: 5.157

2.  Phosphorylation of dopamine transporter serine 7 modulates cocaine analog binding.

Authors:  Amy E Moritz; James D Foster; Balachandra K Gorentla; Michelle S Mazei-Robison; Jae-Won Yang; Harald H Sitte; Randy D Blakely; Roxanne A Vaughan
Journal:  J Biol Chem       Date:  2012-11-16       Impact factor: 5.157

3.  Impact of metabotropic glutamate 2/3 receptor stimulation on activated dopamine release and locomotion.

Authors:  Alan L Pehrson; Bita Moghaddam
Journal:  Psychopharmacology (Berl)       Date:  2010-06-29       Impact factor: 4.530

Review 4.  Kinase-dependent Regulation of Monoamine Neurotransmitter Transporters.

Authors:  Daniel P Bermingham; Randy D Blakely
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

5.  Chronic methylphenidate treatment enhances striatal dopamine neurotransmission after experimental traumatic brain injury.

Authors:  Amy K Wagner; Laura L Drewencki; Xiangbai Chen; F Ryan Santos; Amina S Khan; Rashed Harun; Gonzalo E Torres; Adrian C Michael; C Edward Dixon
Journal:  J Neurochem       Date:  2008-12-10       Impact factor: 5.372

Review 6.  Role of the dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuse.

Authors:  J Zhu; M E A Reith
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-11       Impact factor: 4.388

Review 7.  Phosphorylation of the Amino Terminus of the Dopamine Transporter: Regulatory Mechanisms and Implications for Amphetamine Action.

Authors:  Caline S Karam; Jonathan A Javitch
Journal:  Adv Pharmacol       Date:  2017-10-25

8.  Unique Effects of Acute Aripiprazole Treatment on the Dopamine D2 Receptor Downstream cAMP-PKA and Akt-GSK3β Signalling Pathways in Rats.

Authors:  Bo Pan; Jiezhong Chen; Jiamei Lian; Xu-Feng Huang; Chao Deng
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240

9.  HIV Subtypes B and C gp120 and Methamphetamine Interaction: Dopaminergic System Implicates Differential Neuronal Toxicity.

Authors:  Thangavel Samikkannu; Kurapati V K Rao; Abdul Ajees Abdul Salam; Venkata S R Atluri; Elena M Kaftanovskaya; Marisela Agudelo; Suray Perez; Changwon Yoo; Andrea D Raymond; Hong Ding; Madhavan P N Nair
Journal:  Sci Rep       Date:  2015-06-09       Impact factor: 4.379

10.  The effect of alpha-synuclein knockdown on MPP+ toxicity in models of human neurons.

Authors:  Timothy M Fountaine; Lara Lourenco Venda; Nicholas Warrick; Helen C Christian; Patrik Brundin; Keith M Channon; Richard Wade-Martins
Journal:  Eur J Neurosci       Date:  2008-11-21       Impact factor: 3.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.